Skip to main content

Moderna (NASDAQ: MRNA) — Company Overview, News & Financial Data

Moderna logo
MRNA Moderna
Moderna primary media
Company profile

Moderna

About

Explore United States companies

Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA medicines and vaccines. The company utilizes proprietary messenger RNA technology platforms to design therapeutics and preventive vaccines targeting infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular ailments. Its commercial portfolio includes preventive vaccines for viral respiratory pathogens alongside a pipeline of clinical candidates across multiple therapeutic areas. The company maintains biomanufacturing, research, and commercial operations internationally.

Snapshot

Public USOwnership
2010Year founded
1,001–5,000Employees
Cambridge, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
United States
Cambridge, US
Australia
Japan

Products and/or services of Moderna

  • Respiratory Vaccines: Commercial production and global supply of messenger RNA vaccines protecting against respiratory viral infections, including formulations for COVID-19 and respiratory syncytial virus administered across international healthcare markets.
  • Infectious Disease Pipeline: Clinical development of investigational mRNA vaccines targeting latent and emerging pathogens, including cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, herpes simplex virus, and seasonal influenza strains.
  • Immuno-Oncology Therapeutics: Advancement of individualized neoantigen therapies and off-the-shelf mRNA cancer vaccines designed to stimulate targeted T-cell immune responses against specific tumor antigens in combination with checkpoint inhibitors.
  • Rare Disease Therapies: Development of systemic messenger RNA therapeutics designed to instruct human cells to produce functional intracellular or secreted proteins, addressing metabolic deficiencies such as propionic acidemia and methylmalonic acidemia.
  • Autoimmune and Cardiovascular Therapeutics: Clinical research into localized and systemic mRNA formulations designed to express therapeutic proteins, promote angiogenesis, or modulate immune pathways in heart failure, ischemic heart disease, and autoimmune conditions.
  • Manufacturing Facilities: Operation of specialized biomanufacturing plants and technological hubs, including facilities in Norwood, Massachusetts, dedicated to clinical supply production, lipid nanoparticle formulation, and large-scale commercial drug substance manufacturing.

Moderna executive team

  • Mr. Stéphane BancelCEO & Director
  • Dr. Stephen Hoge M.D.President
  • Mr. James M. MockChief Financial Officer
  • Ms. Shannon Thyme Klinger J.D.Chief Legal Officer & Corporate Secretary
  • Dr. Jerh Collins Ph.D.Chief Technical Operations & Quality Officer
  • Ms. Lavina Talukdar CFASenior VP & Head of Investor Relations
  • Ms. Tracey FranklinChief People & Digital Technology Officer
  • Dr. Melanie Ivarsson M.B.A., O.B.E., Ph.D.Chief Development Officer
  • Mr. Dave JohnsonChief Data & AI Officer
  • Dr. Charbel Haber M.P.H., Ph.D.Senior VP & Head of Global Regulatory Science